Evidence map›Paper›PMID 41279970›Full record

ArticlebioRxiv : the preprint server for biology2025

Prognostic and Therapeutic Implications of

Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrozek, Mark J Routbort, Keyur P Patel, Christopher J Walker, Jill Buss, Andrew R Stiff and 22 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

Darren LeeUniversity of Cincinnati College of Medicine, Cincinnati OH.
Yazan Abu-ShihabDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Kate PlasUniversity of Cincinnati, Computational Science Graduate Program, Cincinnati OH.
Deedra NicoletClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus OH.
Krzysztof MrozekDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Mark J RoutbortDepartment of Hematopathology, MD Anderson Cancer Center, Houston TX.
Keyur P PatelDepartment of Hematopathology, MD Anderson Cancer Center, Houston TX.
Christopher J WalkerClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus OH.
Jill BussDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Andrew R StiffDepartment of Internal Medicine, Ohio State University, Columbus, OH.
Andrea LagansonDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Courtney D DiNardoDepartment of Leukemia, MD Anderson Cancer Center, Houston TX.
Naval G DaverDepartment of Leukemia, MD Anderson Cancer Center, Houston TX.
Tapan M KadiaDepartment of Leukemia, MD Anderson Cancer Center, Houston TX.ORCID 0000-0002-9892-9832
Farhad RavandiDepartment of Leukemia, MD Anderson Cancer Center, Houston TX.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL.
Jonathan E KolitzNorthwell Cancer Center, Hofstra/Northwell School of Medicine, Lake Success, NY.
Bayard L PowellAtrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC.
William G BlumWinship Cancer Institute of Emory University School of Medicine, Atlanta GA.
Maria R BaerUniversity of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD.
Guido MarcucciDepartment of Hematology, City of Hope Comprehensive Cancer, Duarte, CA.
Geoffrey L UyDivision of Oncology, Washington University School of Medicine, Saint Louis, MO.
Wendy StockUniversity of Chicago Medicine, Chicago, IL.
Richard M StoneDana-Farber Cancer Institute, Boston MA.
L Jeffrey MedeirosDepartment of Hematopathology, MD Anderson Cancer Center, Houston TX.
John C ByrdUniversity of Cincinnati College of Medicine, Cincinnati OH.
James S BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Robert L BowmanDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA.ORCID 0000-0002-8294-8748
Jeffrey W TynerDepartment of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR.
Sanam LoghaviDepartment of Hematopathology, MD Anderson Cancer Center, Houston TX.ORCID 0000-0001-8980-3202
Ann-Kathrin EisfeldDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Linde A MilesUniversity of Cincinnati Cancer Center, Cincinnati OH.

Funding

Interrogating oncogene-dependency and mutation order in FLT3 mutant AMLR00CA248460 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BOWMAN, ROBERT LYLE · 2022 to 2024
$743k
Dissecting the role of clonal evolution in NPM1-mutant AMLR00CA252005 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI MILES, LINDE A · 2022 to 2024
$669k
Clinician Scientist in LeukemiaR50CA275927 · NCI · WASHINGTON UNIVERSITY · PI GEOFFREY L UY · 2023 to 2026
$531k
NCI NIH HHS R00 CA248460NCI NIH HHS R00 CA252005NCI NIH HHS R50 CA275927
6 · The paper itself

Abstract

Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving

Identifiers

PMID41279970
PMCPMC12632951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.